Our mission

To advance the next generation of immunotherapies that lead T cells to gain control over disease and improve patients’ lives.

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.

Barinthus Biotherapeutics Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile

VTP-200 was generally well-tolerated and was administered with no product-related grade 3 unsolicited adverse events and no product-related serious adverse events (SAEs) in women with low grade human papillomavirus-related cervical lesions…

Barinthus Biotherapeutics Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

Completed Phase 1b/2a trial of VTP-300 met its primary and secondary endpoints VTP-300 is the first antigen-specific immunotherapy shown to induce sustained reductions in Hepatitis B surface antigen (HBsAg) Results will be presented at the upcoming European Association for the Study of the Liver (EASL)…

Barinthus Biotherapeutics Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

Barinthus Biotherapeutics today (March 24, 2023) announced its financial results for year end 2022 and an overview of the Company’s progress.

Helping patients and their families is the guiding principle at the heart of Barinthus Biotherapeutics.

The company stands apart through its broad pipeline, built around four proprietary platform technologies; ChAdOx, MVA, SNAP-TI and SNAP-CI. These platforms are enabling the company to develop antigen-specific immunotherapeutics that aim to optimize the disease-fighting capabilities of T cells and guide them towards a healthy balance.